Literature DB >> 8986141

Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays.

W A Cromlish1, B P Kennedy.   

Abstract

We have utilized the baculovirus expression system to develop an in vitro intact cell assay for screening nonsteroidal anti-inflammatory drug (NSAID) inhibition of the two isozymes of human cyclooxygenase (prostaglandin endoperoxidase synthase, EC 1.14.99.1). Infected Spodoptera frugiperda (sf9) cells expressing either human cyclooxygenase-1 (hCOX-1) or human cyclooxygenase-2 (hCOX-2) were harvested 24 hr postinfection, a time point where all cells are viable and hCOX-1 or hCOX-2 are correctly processed. Cells were distributed to a 96-well plate, preincubated with various NSAIDs, and challenged with 10 microM arachidonic acid; then cyclooxygenase activity was assessed indirectly by prostaglandin E2-specific radioimmunoassay. The rank order of potency of NSAID-mediated inhibitions of hCOX-1 and hCOX-2 paralleled those that have been observed in other cell systems. This sf9 cell-based assay can be utilized for the identification of potent and selective inhibitors of hCOX-1 and/or hCOX-2. Compounds that preferentially inhibit hCOX-2 may provide novel NSAIDs that reduce inflammation while sparing the stomach and kidneys of toxic side-effects seen with current nonselective NSAIDs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8986141     DOI: 10.1016/s0006-2952(96)00599-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate.

Authors:  X M Xu; L Sansores-Garcia; X M Chen; N Matijevic-Aleksic; M Du; K K Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.

Authors:  Karen W Makar; Elizabeth M Poole; Alexa J Resler; Brenna Seufert; Karen Curtin; Sarah E Kleinstein; David Duggan; Richard J Kulmacz; Li Hsu; John Whitton; Christopher S Carlson; Christine F Rimorin; Bette J Caan; John A Baron; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Cancer Causes Control       Date:  2013-12       Impact factor: 2.506

3.  Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry.

Authors:  Hongmei Cao; Rui Yu; Yi Tao; Dejan Nikolic; Richard B van Breemen
Journal:  J Pharm Biomed Anal       Date:  2010-08-13       Impact factor: 3.935

4.  Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.

Authors:  F Giuliano; T D Warner
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

5.  Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells.

Authors:  Zhi-Hong Zhang; Qin Ouyang; Hua-Tian Gan
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

6.  Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs.

Authors:  R Pouplana; J J Lozano; C Pérez; J Ruiz
Journal:  J Comput Aided Mol Des       Date:  2002-10       Impact factor: 3.686

7.  Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.

Authors:  Kotaro Shirakawa; Lan Wang; Na Man; Jasna Maksimoska; Alexander W Sorum; Hyung W Lim; Intelly S Lee; Tadahiro Shimazu; John C Newman; Sebastian Schröder; Melanie Ott; Ronen Marmorstein; Jordan Meier; Stephen Nimer; Eric Verdin
Journal:  Elife       Date:  2016-05-31       Impact factor: 8.140

8.  Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses.

Authors:  Kathrin Buntenkötter; Maren Osmers; Ina Schenk; Wilhelm Schänzer; Marc Machnik; Michael Düe; Manfred Kietzmann
Journal:  BMC Vet Res       Date:  2017-01-19       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.